Live Breaking News & Updates on Saturnv Capital Management
Stay updated with breaking news from Saturnv capital management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 47,700 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, January 10th. The shares were acquired at an average price of $12.67 per share, with a total value of $604,359.00. Following the acquisition, the insider now directly […] ....
Form D/A Saturn V Capital Offshor streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) announced its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.12, MarketWatch Earnings reports. KalVista Pharmaceuticals Trading Down 4.5 % Shares of KalVista Pharmaceuticals stock opened at $10.35 on Friday. KalVista Pharmaceuticals […] ....
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Consensus Recommendation of "Hold" from Analysts kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Tekla Capital Management LLC bought a new stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Free Report) during the 1st quarter, Holdings Channel reports. The firm bought 83,500 shares of the company’s stock, valued at approximately $1,933,000. Other hedge funds have also recently added to or reduced their stakes in the company. Hennion & […] ....